Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma

Figure 9

Possible effect of sorafenib on host immunity. Sorafenib therapy might abrogate escape mechanisms from the host immunity in LC patients with aHCC by inducing Th1 dominance. DC: Dendritic cell, Treg: regulatory T cells, Th1: type 1 helper T cells, Th2: type 2 helper T cells, CTL: cytotoxic CD8⁺ T lymphocytes.